Newsletter | June 14, 2022

06.14.22 -- Accelerate Biologics Development With Strategic CDMO Partnerships

 
Small Pharma, Big Opportunity: 8 Reasons To Look Beyond Size
 

Should CDMO partner size influence selection for your large molecule project? To choose the best CDMO for you, here are a few reminders to help you look beyond size.

Strategic CDMO Partnerships: Leveraging Infrastructure Investments And Innovation To Accelerate Biologics Development
 

Keeping pace with the market dynamics transforming the biologics space requires a focus on innovation and access to the integrated resources necessary to support it. Select the right partner to get promising biological therapies to patients quickly.

5,000L Single-Use Bioreactors: Next-Gen Biologics Manufacturing
 

A new generation of single-use bioreactors, built to deliver high-volume performance, addresses a demand for therapeutics, expanding indications for biologics and a growing portfolio of biosimilars.

CDMO Timebombs: Five Ways The Wrong Partner Can Lead To Trouble
 

A manufacturing partner that can't manage the complexities of your biologic can cause problems large and small, putting your next level of funding, or even the future of your company, in jeopardy.

In-House Versus Outsource: A Decision-Making Guide
 

Biopharmaceutical companies are increasingly seeking new strategies to quickly and cost-effectively bring biologics to market. Executives must consider how outsourcing fits into their development and production strategy and how to select the best CDMO partner for their business.